A robust quarter included a ramp-up in COVID-19-related orders, something Repligen says will set the scene for increased revenues in the second half of 2020. “Our results for the second quarter and through the first half of 2020 have been stellar,†Repligen CEO Tony Hunt told stakeholders last week. “We delivered overall revenue growth of 25%, including organic growth of 19% in the second quarter.†This equates to $164 million for the first half, compared to $131 million over the…
Cytiva, the former GE Healthcare Life Sciences business, is “off to a blistering start†at Danaher, according to an analyst despite face-to-face restrictions imposed by COVID-19. For the second quarter 2020, Danaher Corporation reported revenues of $5.3 billon, up 19% year-on-year. This was attributed to high sales across its life sciences services divisions, including a boost from Cytiva – previously known as the Biopharma Business of GE Life Sciences – which Danaher acquired for $21 billion and became part of…
Thermo Fisher’s revenue increased 10% in the second quarter thanks to $1.3 billion generated by COVID-19 related work. Thermo posted revenue of $6.92 billion, up from $6.32 billion in the comparable quarter last year. Life sciences solutions contributed $2.60 billion – up from $1.71 billion – specialty diagnostics brought in $990 million – up from $940 million – and lab products and services generated $2.79 billion, up from $2.63 billion. In contrast, analytical instrument revenue was $1.05 billion, down from $1.32 billion…
Blockchain tech is ideal for SARS-CoV-2 vaccine supply chains according to an expert who says efficiency and trust are vital. In the six or so months since SARS-CoV2 – the causative agent of COVID-19 – was detected, public health efforts have focused on finding ways to slow the spread of the virus until a vaccine could be developed. In parallel vaccine developers have accelerated their efforts. According to the World Health Organisation (WHO) there are 23 candidate SARS-CoV2 jabs in…
As drugs have become more complex, so too has the supply chain, which must innovate to accommodate the necessary, specialized conditions for the storage and transportation of these drugs, even under extenuating circumstances. As the pharmaceutical industry shifts its attention to biologics and cell and gene therapies, the need for more advanced storage solutions has heightened considerably. In January 2019, former commissioner of the U.S. Food and Drug Administration (FDA) Scott Gottlieb, M.D. issued a statement regarding the impending cell…
Repligen will add silicone single-use consumables and components for bioprocessing functions through the addition of Engineered Molding Technology (EMT). The size of the deal has not been divulged, but Repligen will expand its single-use filtration and chromatography system component portfolio with custom molded and over-molded connectors and silicone tubing products. “The acquisition of EMT expands our line of single-use ProConne® flow paths, streamlines our supply chain for ATF, and gives us more flexibility as we scale and expand our single-use…
Biogen, Amgen, Pfizer, Genentech and Sanofi have teamed with an MIT-led group aiming to develop new biomanufacturing cell lines and methods. The collaboration – known as the AltHost Consortium – will share research to explore innovative ways to produce biologics and vaccines for clinical usage in diseases from diabetes to cancer. Lead researcher Christopher Love from MIT likened the collaboration to the early days of the biopharmaceutical industry. “When biomanufacturing first emerged as a field, shared knowledge across laboratories was…
Cytiva has upgraded its Fast Trak facility in Marlborough in response to demand for pre-clinical to Phase II biomanufacturing services from small to mid-sized companies. Under the firm’s Fast Trak contract development and manufacturing brand, Cytiva has expanded its Marlborough cGMP facility to 60,000 square feet. The plant offers biopharma access to services from preclinical to Phase II, including process development, clinical batch manufacturing, analytical development, and QA/QC/regulatory support. Olivier Loeillot, senior vice president of BioProcess at Cytiva, did not…
Gerresheimer, The Stevanato Group, and SCHOTT have pledged to safeguard the supply of glass vials as demand from COVID-19 related projects gets set to skyrocket. All parts of the biopharma supply chain will be called upon to support the increasing numbers of COVID-19 vaccines entering and progressing through the clinic. As such, three glass and primary packaging firms have come together to issue a statement promising to work together and with industry to ensure supply of such elements throughout all…
The big four bioprocess vendors – Thermo Fisher, Danaher, MilliporeSigma, and Sartorius – are set to benefit from the commercial success of COVID-19 vaccines, according to Evercore ISI. There are a host of vaccine candidates targeting the novel coronavirus (SARS-CoV-2) moving into and through the clinic, and while there is no guarantee of success a breakthrough product will be a lucrative market opportunity. Specifically, a commercialized product could be worth upwards of $100 billion (€89 billion), according to the team…